Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Inovio Pharmaceuticals has received an average recommendation of "Moderate Buy" from five brokerages, with an average 12-month price target of $8.80.
• Institutional investors have increased their holdings in Inovio, with Deep Track Capital LP boosting its position by 72.9% in the most recent quarter.
• The company's most recent earnings report showed an EPS of ($0.61), which was better than the consensus estimate of ($0.63).

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has received an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $8.80.

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, August 14th. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Royal Bank Of Canada restated a "sector perform" rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Oppenheimer cut their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Finally, Piper Sandler assumed coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price objective for the company.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INO. Deep Track Capital LP boosted its position in shares of Inovio Pharmaceuticals by 72.9% during the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company's stock valued at $5,708,000 after purchasing an additional 1,314,796 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $1,922,000. Bank of America Corp DE boosted its holdings in shares of Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock worth $1,173,000 after buying an additional 584,521 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Inovio Pharmaceuticals by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock worth $1,150,000 after buying an additional 6,874 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $412,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Trading Up 20.6%

INO stock opened at $2.46 on Thursday. The firm has a market cap of $130.72 million, a PE ratio of -0.94 and a beta of 1.38. The company has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $1.83. Inovio Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $7.55.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.02. As a group, analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.